Esteve’s Staffan Schüberg on Mid-Cap Innovation, Generics Divestment &…
Way before securing the CEO role at Esteve in 2018, Staffan Schüberg built a career that saw him rise through the ranks of Lundbeck, from commercial activities in Sweden to…
Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Iberia, S.L.
Paseo de la Castellana 41 – 3a
28046 Madrid
Spain
Phone: +34 91 310 71 10
Fax: +34 91 310 71 11
www.biogenidec.es
Way before securing the CEO role at Esteve in 2018, Staffan Schüberg built a career that saw him rise through the ranks of Lundbeck, from commercial activities in Sweden to…
Ignacio Vega, CEO of Cardiva and Cardivais, a Spanish medtech producer and distributor, explains how, as a manufacturer of PPE, the company had to reconfigure its production operations to supply…
Esteve’s CEO outlines the transformation journey of the Spanish company after taking over in 2018, commenting on how the divestment of its generics business has helped the company lay the…
Teva’s general manager for Spain and Portugal, Juan Carlos Conde Ibarra, dives into the recently announced strategy for the affiliate, including the move to a single brand in generics, and…
Margarita Alfonsel, general secretary of Fenin, the Spanish Federation of Healthcare Technology Companies, reflects on the COVID-19 pandemic, the changing dynamics of the medical technology industry in Spain, and comments…
AseBio is the association promoting the development of the Spanish biotechnology industry. Its general manager, Ion Arocena, lays out the main priorities for the country’s sector, including the need to…
Kern Pharma’s chairman and Grupo Indukern CEO, Raúl Díaz-Varela, explains the new strategic direction of the Spanish generics player, how their partnership with Celltrion to commercialise biosimilars has evolved, and…
HIPRA is a world-leading animal health company that has launched a record 22 animal vaccines in the last 10 years. During the COVID-19 pandemic, the European company decided to jump…
The Vall d’Hebron Institute of Oncology (VHIO) is a Barcelona-based institute dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments…
Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is…
Alta Life Sciences is one of Catalonia’s top venture capital investor groups in the biotech sector. Montserrat Vendrell, partner and a pivotal figure in the development of the region’s life…
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
See our Cookie Privacy Policy Here
